Novartis' Cosentyx Fails Late-Stage Giant Cell Arteritis Trial

Novartis AG (NYSE:NVS) on Thursday released topline results from the Phase 3 GCAptAIN study evaluating Cosentyx (secukinumab) for newly diagnosed or relapsing giant cell arteritis (GCA).

Giant cell arteritis is an inflammation of the lining of the arteries. It often affects the arteries in the head, especially those in the temples.

In the study, Cosentyx was evaluated with a 26-week steroid taper and compared to a placebo plus a 52-week steroid taper. Cosentyx did not demonstrate a statistically significant improvement in sustained remission at Week 52 compared to placebo.

Also Read: FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers

While the secondary outcomes did not show statistical superiority, Cosentyx showed numerically better outcomes ...